235 related articles for article (PubMed ID: 37389830)
41. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
Berg SL; Blaney SM; Devidas M; Lampkin TA; Murgo A; Bernstein M; Billett A; Kurtzberg J; Reaman G; Gaynon P; Whitlock J; Krailo M; Harris MB;
J Clin Oncol; 2005 May; 23(15):3376-82. PubMed ID: 15908649
[TBL] [Abstract][Full Text] [Related]
43. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
[TBL] [Abstract][Full Text] [Related]
44. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
[TBL] [Abstract][Full Text] [Related]
45. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
46. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
47. Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults.
Patel AA; Thomas J; Rojek AE; Stock W
Curr Treat Options Oncol; 2020 May; 21(7):57. PubMed ID: 32468488
[TBL] [Abstract][Full Text] [Related]
48. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
49. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
50. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols.
Michaux K; Bergeron C; Gandemer V; Mechinaud F; Uyttebroeck A; Bertrand Y;
Pediatr Blood Cancer; 2016 Jul; 63(7):1214-21. PubMed ID: 27037853
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
Temple WC; Mueller S; Hermiston ML; Burkhardt B
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101449. PubMed ID: 36907639
[TBL] [Abstract][Full Text] [Related]
52. Nelarabine in the treatment of refractory T-cell malignant diseases.
Kline J; Larson RA
Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
[TBL] [Abstract][Full Text] [Related]
53. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
[No Abstract] [Full Text] [Related]
54. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
Borthakur G; Martinelli G; Raffoux E; Chevallier P; Chromik J; Lithio A; Smith CL; Yuen E; Oakley GJ; Benhadji KA; DeAngelo DJ
Cancer; 2021 Feb; 127(3):372-380. PubMed ID: 33107983
[TBL] [Abstract][Full Text] [Related]
55. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
[TBL] [Abstract][Full Text] [Related]
56. Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial?
Agrawal AK; Michlitsch J; Golden C; Hastings CA; Raphael R; Feusner JH
J Clin Oncol; 2021 Feb; 39(6):694. PubMed ID: 33444071
[No Abstract] [Full Text] [Related]
57. Nelarabine.
Sanford M; Lyseng-Williamson KA
Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
[TBL] [Abstract][Full Text] [Related]
58. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010.
Gao YJ; Pan C; Tang JY; Lu FJ; Chen J; Xue HL; Zhai XW; Li J; Ye QD; Zhou M; Wang HS; Miao H; Qian XW; Xu Z; Meng JH
Pediatr Blood Cancer; 2014 Apr; 61(4):659-63. PubMed ID: 24243691
[TBL] [Abstract][Full Text] [Related]
59. [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
Iino M
Rinsho Ketsueki; 2009 Jan; 50(1):49-51. PubMed ID: 19225230
[TBL] [Abstract][Full Text] [Related]
60. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]